Suchergebnisse - "Panteleimon Charitos"

PubPharm (5)

1

Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial

in: Frontiers in Immunology | 2023

von Pascal Urwyler | Marina Leimbacher | Panteleimon Charitos | +16

2

Complement and endothelial cell activation in COVID-19 patients compared to controls with suspected SARS-CoV-2 infection: A prospective cohort study

in: Frontiers in Immunology | 2022

von Flavio Bruni | Panteleimon Charitos | Maurin Lampart | +10

3

Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)

in: Trials | 2021

von Pascal Urwyler | Panteleimon Charitos | Stephan Moser | +11

4

Functional Activity of the Complement System in Hospitalized COVID-19 Patients: A Prospective Cohort Study

in: Frontiers in Immunology | 2021

von Panteleimon Charitos | Ingmar A. F. M. Heijnen | Adrian Egli | +8

5

Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System

in: Frontiers in Immunology | 2020

von Pascal Urwyler | Stephan Moser | Panteleimon Charitos | +11

1
[1]